{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:51:40Z","timestamp":1792608700685,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung adenocarcinoma (LUAD) is a predominant contributor to cancer\u2011related mortality globally. Lung\u2011associated fibroblasts (LAFs) are intricately linked to tumorigenesis and the tumor microenvironment (TME), but their heterogeneity and prognostic relevance in LUAD remain incompletely understood. This study aimed to systematically characterize LAF subsets across the spectrum of pulmonary disease, identify LAF subpopulations associated with LUAD prognosis, and construct a robust LAF\u2011based prognostic signature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed a multi-omics approach, leveraging bulk RNA data of 2719 patients from 19 LUAD cohorts, single-cell RNA (scRNA) sequencing data of 368,904 cells from 93 samples, and spatial transcriptomics data of 15,673 spots from 6 samples to characterize the landscape of LAFs across various stages of pulmonary disease. We employed multiple advanced machine learning algorithms to construct and validate a robust nuclear division LAFs (nLAFs) risk score (nLRS) prediction model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed a dynamic and gradual increase in the proportion of LAFs during the progression of LUAD. Throughout this process, we identified nine LAFs subtypes and found nLAFs are significantly associated with the prognosis of LUAD. Utilizing 100 machine learning algorithm combinations and integrating nLAFs marker genes, we developed a five gene based nLRS model, which demonstrated superior performance than other 49 published models in predicting clinical outcomes for LUAD. Additionally, we observed distinct biological functions and immune cell infiltration in the TME between high and low nLRS groups. Exploratory analysis of pan-cancer immunotherapy cohorts suggested that patients with high nLRS scores may exhibit resistance to immunotherapy in some cancer types, but prospective validation in LUAD-specific cohorts is required. Conversely, high nLRS patients displayed increased sensitivity to chemotherapeutic and targeted therapies in preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study introduces a candidate five-gene signature derived from nLAFs that may serve as a robust prognostic biomarker pending prospective validation, offering insights into personalized therapeutic strategies for LUAD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08022-3","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:53:33Z","timestamp":1774022013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets"],"prefix":"10.1186","volume":"24","author":[{"given":"Peng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingtao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9800-3319","authenticated-orcid":false,"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"1","key":"8022_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Ca-Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"Ca-Cancer J Clin"},{"key":"8022_CR2","doi-asserted-by":"crossref","unstructured":"Brody H. Lung cancer. NATURE. 2020;587(7834):S7.","DOI":"10.1038\/d41586-020-03152-0"},{"key":"8022_CR3","doi-asserted-by":"crossref","unstructured":"Tan WL, Jain A, Takano A, et al. Novel therapeutic targets on the horizon for lung cancer. The Lancet Oncol. 2016;17(8):e347\u201362.","DOI":"10.1016\/S1470-2045(16)30123-1"},{"issue":"12","key":"8022_CR4","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012\u201324.","journal-title":"Clin Cancer Res"},{"issue":"34","key":"8022_CR5","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1200\/JCO.2008.16.7254","volume":"26","author":"T Takano","year":"2008","unstructured":"Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Educ Chang Clin Oncol. 2008;26(34):5589\u201395.","journal-title":"J Educ Chang Clin Oncol"},{"issue":"7801","key":"8022_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2099-x","volume":"580","author":"K Han","year":"2020","unstructured":"Han K, Pierce SE, Li A, et al. CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. NATURE. 2020;580(7801):136\u201341.","journal-title":"NATURE"},{"issue":"14","key":"8022_CR7","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1158\/1078-0432.CCR-18-2439","volume":"25","author":"CM Lusk","year":"2019","unstructured":"Lusk CM, Watza D, Dyson G, et al. Profiling the mutational landscape in known Driver genes and Novel genes in African American non-small cell lung cancer patients. Clin Cancer Res. 2019;25(14):4300\u201308.","journal-title":"Clin Cancer Res"},{"key":"8022_CR8","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/ncomms14768","volume":"8","author":"K Uchibori","year":"2017","unstructured":"Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017;8:14768.","journal-title":"Nat Commun"},{"key":"8022_CR9","doi-asserted-by":"crossref","unstructured":"Cheng ZHJJJ. Integrating machine learning and multi-omics to identify key SUMOylation molecular signature in sarcoma. Life Conflux. 2025.","DOI":"10.71321\/lcflx.00001"},{"key":"8022_CR10","doi-asserted-by":"crossref","unstructured":"Zhuang LJYFZ. Deciphering the multifaceted significance of MPZL2 in pancreatic cancer via in-depth bioinformatics analyses. Life Conflux. 2025.","DOI":"10.71321\/75r4yp80"},{"issue":"8","key":"8022_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc.2016.56","volume":"16","author":"AJ Vargas","year":"2016","unstructured":"Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16(8):525\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8022_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"GQ Zhu","year":"2023","unstructured":"Zhu GQ, Tang Z, Huang R, et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9(1):25.","journal-title":"Cell Discov"},{"issue":"1","key":"8022_CR13","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ye SY, He S, et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat Commun. 2024;15(1):7713.","journal-title":"Nat Commun"},{"issue":"1","key":"8022_CR14","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1038\/s41467-024-50478-8","volume":"15","author":"W Li","year":"2024","unstructured":"Li W, Pan L, Hong W, et al. A single-cell pan-cancer analysis to show the variability of tumor-infiltrating myeloid cells in immune checkpoint blockade. Nat Commun. 2024;15(1):6142.","journal-title":"Nat Commun"},{"issue":"10","key":"8022_CR15","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.ccell.2024.08.020","volume":"42","author":"Y Gao","year":"2024","unstructured":"Gao Y, Li J, Cheng W, et al. Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. Cancer Cell. 2024;42(10):1764\u201383.","journal-title":"Cancer Cell"},{"issue":"8","key":"8022_CR16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu G, Zeng Q, et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 2024;42(8):1370\u201385.","journal-title":"Cancer Cell"},{"issue":"1","key":"8022_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12943-023-01876-x","volume":"22","author":"C Ma","year":"2023","unstructured":"Ma C, Yang C, Peng A, et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol Cancer. 2023;22(1):170.","journal-title":"Mol Cancer"},{"issue":"12","key":"8022_CR18","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.7150\/thno.99046","volume":"14","author":"F Long","year":"2024","unstructured":"Long F, Zhong W, Zhao F, et al. DAB2 (+) macrophages support FAP (+) fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer. Theranostics. 2024;14(12):4822\u201343.","journal-title":"Theranostics"},{"issue":"1","key":"8022_CR19","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Xia X, Huang L, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619.","journal-title":"Nat Commun"},{"issue":"8","key":"8022_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"1","key":"8022_CR21","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim N, Kim HK, Lee K, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11(1):2285.","journal-title":"Nat Commun"},{"key":"8022_CR22","doi-asserted-by":"crossref","unstructured":"Adams TS, Schupp JC, Poli S, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv. 2020;6(28):eaba1983.","DOI":"10.1126\/sciadv.aba1983"},{"issue":"24","key":"8022_CR23","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/onc.2015.375","volume":"35","author":"MB Schabath","year":"2016","unstructured":"Schabath MB, Welsh EA, Fulp WJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. ONCOGENE. 2016;35(24):3209\u201316.","journal-title":"ONCOGENE"},{"issue":"1","key":"8022_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/0008-5472.CAN-11-1403","volume":"72","author":"H Okayama","year":"2012","unstructured":"Okayama H, Kohno T, Ishii Y, et al. Identification of genes upregulated in ALK-positive and EGFR\/KRAS\/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72(1):100\u201311.","journal-title":"Cancer Res"},{"issue":"1","key":"8022_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/JTO.0000000000000042","volume":"9","author":"SD Der","year":"2014","unstructured":"Der SD, Sykes J, Pintilie M, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol. 2014;9(1):59\u201364.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"8022_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13148-020-00907-4","volume":"12","author":"JY Kim","year":"2020","unstructured":"Kim JY, Choi JK, Jung H. Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer. Clin Epigenet. 2020;12(1):119.","journal-title":"Clin Epigenet"},{"issue":"4","key":"8022_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. CELL. 2017;171(4):934\u201349.","journal-title":"CELL"},{"issue":"12","key":"8022_CR28","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","volume":"28","author":"A Necchi","year":"2017","unstructured":"Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044\u201350.","journal-title":"Ann Oncol"},{"issue":"1","key":"8022_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. CELL. 2016;165(1):35\u201344.","journal-title":"CELL"},{"issue":"1","key":"8022_CR30","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"MD Zuani","year":"2024","unstructured":"Zuani MD, Xue H, Park JS, et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. 2024;15(1):4388.","journal-title":"Nat Commun"},{"key":"8022_CR31","doi-asserted-by":"crossref","unstructured":"Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955\u201361.","DOI":"10.1093\/nar\/gks1111"},{"issue":"1","key":"8022_CR32","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Xia X, Huang LB, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619.","journal-title":"Nat Commun"},{"issue":"1","key":"8022_CR33","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Fan J, He Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12(1):2540.","journal-title":"Nat Commun"},{"issue":"4","key":"8022_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8(4):329\u201337.","journal-title":"Cell Syst"},{"issue":"1","key":"8022_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41698-024-00538-5","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang R, Hu D, Zhang C, Cao P, Huang J. Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy. NPJ Precis Oncol. 2024;8(1):49.","journal-title":"NPJ Precis Oncol"},{"key":"8022_CR36","unstructured":"Zhanghao. zhanghao-njmu.github.io\/SCP\/, \u201c, pp."},{"issue":"7938","key":"8022_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue R, Zhang Q, Cao Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. NATURE. 2022;612(7938):141\u201347.","journal-title":"NATURE"},{"issue":"10","key":"8022_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu X, Mao Q, Tang Y, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14(10):979\u201382.","journal-title":"Nat Methods"},{"issue":"1","key":"8022_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s12864-018-4772-0","volume":"19","author":"K Street","year":"2018","unstructured":"Street K, Risso D, Fletcher RB, et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics. 2018;19(1):477.","journal-title":"BMC Genomics"},{"issue":"4","key":"8022_CR40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41587-021-01091-3","volume":"40","author":"D Sun","year":"2022","unstructured":"Sun D, Guan X, Moran AE, et al. Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol. 2022;40(4):527\u201338.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"8022_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2020;17(2):159\u201362.","journal-title":"Nat Methods"},{"issue":"1","key":"8022_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2025;20(1):180\u2013219.","journal-title":"Nat Protoc"},{"key":"8022_CR43","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1016\/j.csbj.2024.06.035","volume":"23","author":"H Liu","year":"2024","unstructured":"Liu H, Zhang W, Zhang Y, et al. Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection. Comput Struct Biotechnol J. 2024;23:2798\u2013810.","journal-title":"Comput Struct Biotechnol J"},{"key":"8022_CR44","doi-asserted-by":"publisher","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng D, Ye Z, Shen R, et al. IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Front Immunol. 2021;12:687975.","journal-title":"Front Immunol"},{"issue":"4","key":"8022_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. IMMUNITY. 2018;48(4):812\u201330.","journal-title":"IMMUNITY"},{"issue":"10","key":"8022_CR46","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u201358.","journal-title":"Nat Med"},{"issue":"43","key":"8022_CR47","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U States Am. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U States Am"},{"key":"8022_CR48","doi-asserted-by":"crossref","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Briefings Bioinf. 22(6):2021.","DOI":"10.1093\/bib\/bbab260"},{"issue":"2","key":"8022_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s13167-024-00362-8","volume":"15","author":"D Hu","year":"2024","unstructured":"Hu D, Shen X, Gao P, et al. Multi-omic profiling reveals potential biomarkers of hepatocellular carcinoma prognosis and therapy response among mitochondria-associated cell death genes in the context of 3P medicine. EPMA J. 2024;15(2):321\u201343.","journal-title":"EPMA J"},{"issue":"8","key":"8022_CR50","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41587-022-01233-1","volume":"40","author":"R Wei","year":"2022","unstructured":"Wei R, He S, Bai S, et al. Spatial charting of single-cell transcriptomes in tissues. Nat Biotechnol. 2022;40(8):1190\u201399.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"8022_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387\u201391.","journal-title":"Br J Cancer"},{"issue":"12","key":"8022_CR52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s40273-017-0563-8","volume":"35","author":"H Albaba","year":"2017","unstructured":"Albaba H, Lim C, Leighl NB. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. PHARMACOECONOMICS. 2017;35(12):1195\u2013209.","journal-title":"PHARMACOECONOMICS"},{"issue":"2","key":"8022_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","volume":"76","author":"M Grunnet","year":"2012","unstructured":"Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138\u201343.","journal-title":"Lung Cancer"},{"issue":"6","key":"8022_CR54","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<939::AID-IJC16>3.0.CO;2-Z","volume":"81","author":"Y Ueda","year":"1999","unstructured":"Ueda Y, Fujita J, Bandoh S, et al. Expression of cytokeratin 19 mRNA in human lung cancer cell lines. Int J Cancer. 1999;81(6):939\u201343.","journal-title":"Int J Cancer"},{"issue":"6349","key":"8022_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"26","key":"8022_CR56","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. NEJM Evid. 2015;372(26):2509\u201320.","journal-title":"NEJM Evid"},{"key":"8022_CR57","unstructured":"Zhang J. ClusterGVis: One-step to Cluster and Visualize Gene Expression Matrix. https:\/\/github.com\/junjunlab\/ClusterGVis ,\u201d,pp.2022."},{"issue":"5","key":"8022_CR58","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-17-2033","volume":"24","author":"EK Duperret","year":"2018","unstructured":"Duperret EK, Trautz A, Ammons D, et al. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res. 2018;24(5):1190\u2013201.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8022_CR59","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41416-024-02671-1","volume":"130","author":"L Mathieson","year":"2024","unstructured":"Mathieson L, Koppensteiner L, Dorward DA, O\u2019Connor RA, Akram AR. Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome. Br J Cancer. 2024;130(11):1758\u201369.","journal-title":"Br J Cancer"},{"issue":"3","key":"8022_CR60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396\u2013412.","journal-title":"Cancer Cell"},{"key":"8022_CR61","doi-asserted-by":"crossref","unstructured":"Herzog BH, Baer JM, Borcherding N, et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Sci Transl Med. 2023;15(699):eadh8005.","DOI":"10.1126\/scitranslmed.adh8005"},{"issue":"2","key":"8022_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99\u2013115.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"8022_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41467-023-35793-w","volume":"14","author":"JM Houthuijzen","year":"2023","unstructured":"Houthuijzen JM, de Bruijn R, van der Burg E, et al. CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer. Nat Commun. 2023;14(1):183.","journal-title":"Nat Commun"},{"key":"8022_CR64","doi-asserted-by":"publisher","first-page":"550002","DOI":"10.3389\/fonc.2020.550002","volume":"10","author":"J Xu","year":"2020","unstructured":"Xu J, Nie H, He J, et al. Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. Front Oncol. 2020;10:550002.","journal-title":"Front Oncol"},{"issue":"4","key":"8022_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1594","volume":"5","author":"MT Lotze","year":"2005","unstructured":"Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331\u201342.","journal-title":"Nat Rev Immunol"},{"key":"8022_CR66","doi-asserted-by":"crossref","unstructured":"Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. MOLECULES. 2016;21(7).","DOI":"10.3390\/molecules21070965"},{"issue":"1","key":"8022_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cell.2018.03.001","volume":"173","author":"A Longchamp","year":"2018","unstructured":"Longchamp A, Mirabella T, Arduini A, et al. Amino Acid Restriction Triggers Angiogenesis via GCN2\/ATF4 Regulation of VEGF and H(2)S Production. CELL. 2018;173(1):117\u201329.","journal-title":"CELL"},{"issue":"4","key":"8022_CR68","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-14-2198","volume":"21","author":"IL Romero","year":"2015","unstructured":"Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015;21(4):680\u201386.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"8022_CR69","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","volume":"64","author":"A Neesse","year":"2015","unstructured":"Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. GUT. 2015;64(9):1476\u201384.","journal-title":"GUT"},{"issue":"8","key":"8022_CR70","doi-asserted-by":"publisher","first-page":"114550","DOI":"10.1016\/j.celrep.2024.114550","volume":"43","author":"Q Wang","year":"2024","unstructured":"Wang Q, Song X, Zhang Y, et al. A pro-metastatic tRNA fragment drives aldolase A oligomerization to enhance aerobic glycolysis in lung adenocarcinoma. Cell Rep. 2024;43(8):114550.","journal-title":"Cell Rep"},{"issue":"3","key":"8022_CR71","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/mmr.2023.13064","volume":"28","author":"L Sheng","year":"2023","unstructured":"Sheng L, Kang Y, Chen D, Shi L. Knockdown of ANLN inhibits the progression of lung adenocarcinoma via pyroptosis activation. Mol Med Rep. 2023;28(3):177.","journal-title":"Mol Med Rep"},{"issue":"1","key":"8022_CR72","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ncrna.2023.11.013","volume":"9","author":"Z Ting","year":"2023","unstructured":"Ting Z, Wu Z, Yang C, et al. lncRNA CERS6-AS1 upregulates the expression of ANLN by sponging miR-424-5p to promote the progression and drug resistance of lung adenocarcinoma. Noncoding RNA Res. 2023;9(1):221\u201335.","journal-title":"Noncoding RNA Res"},{"issue":"3","key":"8022_CR73","doi-asserted-by":"publisher","first-page":"408","DOI":"10.21037\/tlcr-22-571","volume":"12","author":"A Nagoya","year":"2023","unstructured":"Nagoya A, Sada R, Kimura H, et al. CKAP4 is a potential exosomal biomarker and therapeutic target for lung cancer. Transl Lung Cancer Res. 2023;12(3):408\u201326.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"8022_CR74","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-017-0682-z","volume":"16","author":"P Zhan","year":"2017","unstructured":"Zhan P, Zhang B, Xi G, et al. PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt\/\u03b2-catenin signaling pathway. Mol Cancer. 2017;16(1):108.","journal-title":"Mol Cancer"},{"key":"8022_CR75","doi-asserted-by":"publisher","first-page":"756094","DOI":"10.3389\/fgene.2021.756094","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Gu W, Wen W, Zhang X. SERPINH1 is a Potential Prognostic Biomarker and Correlated With Immune Infiltration: A Pan-Cancer Analysis. Front Genet. 2021;12:756094.","journal-title":"Front Genet"},{"key":"8022_CR76","doi-asserted-by":"crossref","unstructured":"Zhao G, Song T, Qing Q, Cheng H, Zhao J. SERPINH1 as a Novel Biomarker for Colon Cancer Bone Metastasis with Machine Learning and Immunohistochemistry Validation. Cancer Biother Radiopharm. 2024.","DOI":"10.1089\/cbr.2024.0162"},{"key":"8022_CR77","doi-asserted-by":"publisher","first-page":"933165","DOI":"10.3389\/fimmu.2022.933165","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S, Fu Y, Kuerban K, et al. Discoidin domain receptor 1 is a potential target correlated with tumor invasion and immune infiltration in gastric cancer. Front Immunol. 2022;13:933165.","journal-title":"Front Immunol"},{"key":"8022_CR78","doi-asserted-by":"crossref","unstructured":"Yamaguchi H, Miyazaki M. Heterocellular Adhesion in Cancer Invasion and Metastasis: Interactions between Cancer Cells and Cancer-Associated Fibroblasts. Cancers. 16(9):2024.","DOI":"10.3390\/cancers16091636"},{"issue":"6","key":"8022_CR79","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrc3726","volume":"14","author":"DM Gilkes","year":"2014","unstructured":"Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430\u201339.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08022-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08022-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:02:16Z","timestamp":1777428136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08022-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8022"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08022-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was granted by Anhui Chest Hospital. Written informed consent was obtained from all participants, and the research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"Not commissioned, externally peer-reviewed","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}}],"article-number":"610"}}